{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:52:57Z","timestamp":1793649177155,"version":"4.5.1"},"reference-count":150,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82473759"],"award-info":[{"award-number":["82473759"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2026,9,2]]},"DOI":"10.1080\/13543776.2026.2704853","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T01:01:01Z","timestamp":1785200461000},"page":"865-891","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["A patent review of mutant-selective PI3K\u03b1 inhibitors for the treatment of different cancers (2021\u20132025)"],"prefix":"10.1080","volume":"36","author":[{"given":"Haixiang","family":"Qi","sequence":"first","affiliation":[{"name":"Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]},{"name":"Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayang","family":"Wen","sequence":"additional","affiliation":[{"name":"Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]},{"name":"Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Xu","sequence":"additional","affiliation":[{"name":"Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]},{"name":"Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.029"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2882"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1135394"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.093773"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1056"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1096502"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602970"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3860"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0701005104"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0908444106"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712169105"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml200156t"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800295d"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14683"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30376-5"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00106-6"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850461"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0865"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.001"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0343-4"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2019.03.010"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0945"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.59717\/j.xinn-med.2024.100056"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1021\/jp506423e"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-P4-08-02"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0944"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0396"},{"key":"e_1_3_5_32_1","first-page":"373","volume-title":"Drug discovery stories","author":"Hou Y","year":"2026","unstructured":"Hou Y, Yuan K, Min W, et al. Chapter 26 - STX-478, RLY-2608, and LOXO-783: third-generation PIK3CA mutant-selective allosteric inhibitors. In: Yu B Zhan P, editors. Drug discovery stories. Vol. 2. Netherlands: Elsevier; 2026. p. 373\u2013394."},{"key":"e_1_3_5_33_1","unstructured":"Relay Therapeutics Inc. First-in-human study of mutant-selective PI3K\u03b1 inhibitor RLY-2608 as a single agent in patients with advanced Solid tumors and in combination with endocrine therapy +\/- a CDK4\/6 or CDK4 inhibitor in patients with advanced Solid tumors or advanced breast cancer. [cited 2026 Apr 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05216432"},{"key":"e_1_3_5_34_1","unstructured":"Relay Therapeutics Inc. A phase 2 study of mutant-selective PI3K\u03b1 inhibitor RLY-2608 in adults and children with PIK3CA related overgrowth spectrum and malformations driven by PIK3CA mutation. [cited 2026 Apr 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06789913"},{"key":"e_1_3_5_35_1","unstructured":"Relay Therapeutics Inc. Phase 3 study of RLY-2608 + fulvestrant vs capivasertib + fulvestrant as treatment for locally advanced or metastatic PIK3CA-mutant HR+\/HER2- breast cancer (ReDiscover-2). [cited 2026 Apr 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06982521"},{"key":"e_1_3_5_36_1","unstructured":"Relay Therapeutics Inc. First-in-human study of RLY-5836 in advanced breast cancer and other Solid tumors. [cited 2026 Apr 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05759949"},{"key":"e_1_3_5_37_1","unstructured":"Eli Lilly and Company. A study of LOXO-783 in patients with breast cancer\/other Solid tumors (PIKASSO-01). [cited 2026 Apr 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05307705"},{"key":"e_1_3_5_38_1","unstructured":"Eli Lilly and Company. First-in-human study of tersolisib (STX-478) as monotherapy and in combination with other antineoplastic agents in participants with advanced Solid tumors (PIKALO-1). [cited 2026 Apr 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05768139"},{"key":"e_1_3_5_39_1","unstructured":"Eli Lilly and Company. A study of tersolisib (LY4064809\/STX-478) with other anti-cancer treatments in participants with advanced breast cancer with a genetic change (PIK3CA). [cited 2026 Apr 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07174336"},{"key":"e_1_3_5_40_1","unstructured":"OnKure Inc. First-in-human study of OKI-219 in advanced Solid tumors and advanced breast cancer (PIKture-01). [cited 2026 Apr 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06239467"},{"key":"e_1_3_5_41_1","unstructured":"Ensem Therapeutics. Phase 1\/2 study of ETX-636 in participants with advanced Solid tumors. [cited 2026 Apr 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06993844"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00078"},{"key":"e_1_3_5_43_1","unstructured":"Anderson ED Aronow SD Boyles NA et al. inventors; Petra Pharma Corporation assignee. Preparation of chromenones as allosteric inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of diseases associated with PI3K modulation patent WO2021202964. 2021."},{"key":"e_1_3_5_44_1","unstructured":"Anderson ED Aronow SD Boyles NA et al. inventors; Petra Pharma Corporation assignee. Allosteric chromenones as inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease and their preparation patent WO2022235574. 2022."},{"key":"e_1_3_5_45_1","unstructured":"Anderson ED Aronow SD Boyles NA et al. inventors; Petra Pharma Corporation assignee. Allosteric chromenones as inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease and their preparation patent WO2022235575. 2022."},{"key":"e_1_3_5_46_1","unstructured":"Hao X Lei Y inventors; Nanjing Zenshine Pharmaceuticals Co. Ltd. assignee. Synthesis of fused heterocyclic PI3k\u03b1 inhibitors treating cancers patent WO2023104111. 2023."},{"key":"e_1_3_5_47_1","unstructured":"Anderson ED Aronow SD Boyles NA et al. inventors; Petra Pharma Corporation assignee. Chromenones as allosteric inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of cancer and their preparation patent WO2022251482. 2022."},{"key":"e_1_3_5_48_1","unstructured":"Hickey ER Kesicki EA inventors; Petra Pharma Corporation assignee. Allosteric chromenones as phosphoinositide 3-kinase (PI3k) inhibitors and their preparation pharmaceutical compositions and use in the treatment of cancer patent WO2023056407. 2023."},{"key":"e_1_3_5_49_1","unstructured":"Liu F Feng W Gu J et al. Preparation of 4H-chromen-4-one derivatives as anticancer agents patent CN117430592. 2024."},{"key":"e_1_3_5_50_1","unstructured":"Zhang C Zhao M Liu H et al. inventors; Tibet Haisco Pharmaceutical Co. Ltd. assignee. Preparation of ((oxochromenyl)ethyl)aminoarylcarboxylic acids as PI3K alpha inhibitor patent CN118084844. 2024."},{"key":"e_1_3_5_51_1","unstructured":"Baker SJ Perry MA Liu CY et al. inventors; Reactive Biosciences Inc. AN2 Therapeutics Inc. assignee. Preparation of chromenones and analogs as phosphatidylinositol 3 kinase inhibitors for treating cancers patent WO2025007074. 2025."},{"key":"e_1_3_5_52_1","unstructured":"Aronow SD Jette CI Kolakowski GR et al. inventors; Petra Pharma Corporation assignee. Allosteric chromenone derivatives as PI3K inhibitors for the treatment of disease and their preparation patent WO2023212693. 2023."},{"key":"e_1_3_5_53_1","unstructured":"Dawadi S Wang H-Y Sainz MA et al. inventors; Petra Pharma Corporation assignee. Preparation of allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease patent WO2024097172. 2024."},{"key":"e_1_3_5_54_1","unstructured":"Liu F Feng W Gu J et al. inventors; Chia Tai Tianqing Pharmaceutical Group Co. Ltd. assignee. Preparation of benzopyran compounds for antitumor agents patent CN118084896. 2024."},{"key":"e_1_3_5_55_1","unstructured":"Liu CY Plattner JJ Heerding DA et al. inventors; Reactive Biosciences Inc. assignee. Aminochromenone-derived arylboronic acids and boron heterocycles as phosphatidylinositol 3 kinase inhibitors for treatment of tumor diseases patent WO2024192309. 2024."},{"key":"e_1_3_5_56_1","unstructured":"Wang H-Y inventor; Petra Pharma Corporation assignee. Preparation of (R)-3-[6-chloro-3-[[1-(2-cyclopropyl-6-fluoro-3-methyl-4-oxo-4H-chromen-8-yl)ethyl]amino]pyridin-2-yl]-1 2 4-oxadiazol-5(4H)-one as PI3K inhibitors for the treatment of cancer patent WO2025221919. 2025."},{"key":"e_1_3_5_57_1","unstructured":"Dai X Yu Y Yang H et al. inventors; InventisBio Co. Ltd. InventisBio LLC assignee. Preparation of substituted quinazolinones and related compounds and uses thereof patent WO2023207881. 2023."},{"key":"e_1_3_5_58_1","unstructured":"Tan H Li Z Liu B et al. inventors; Fochon Biosciences Ltd. assignee. Preparation of quinazolines and related heterocycles as protein kinase inhibitors useful in treatment and prevention of PI3K-mediated diseases patent WO2023078401. 2023."},{"key":"e_1_3_5_59_1","unstructured":"Xu H He C Zhou Z et al. inventors; Fochon Biosciences Ltd. assignee. Preparation of quinazolinone and pyridopyrimidinone compounds as protein kinase inhibitors patent WO2024099437. 2024."},{"key":"e_1_3_5_60_1","unstructured":"Busch B Stock NS Nagle A et al. inventors; Genesis Therapeutics Inc. assignee. Preparation of substituted quinazolines and quinolines for treating cancer patent WO2024081904. 2024."},{"key":"e_1_3_5_61_1","unstructured":"Liu B Gao F Guo Y et al. inventors; Suzhou Puhe Biopharma Co. Ltd. assignee. PI3k\u03b1 allosteric inhibitor patent CN117186093. 2023."},{"key":"e_1_3_5_62_1","unstructured":"Orr STM Boren BC Do Q-Q et al. inventors; Zeno Management Inc. assignee. PI3K inhibitors and methods of treating cancer patent WO2023081209. 2023."},{"key":"e_1_3_5_63_1","unstructured":"Fan L Yu H Wang F et al. inventors; Hinova Pharmaceuticals Inc. assignee. PI3K inhibitor and preparation method therefor and use thereof patent WO2025087295. 2025."},{"key":"e_1_3_5_64_1","unstructured":"Chen C Holmes R Maity S et al. inventors; Prelude Therapeutics Incorporated assignee. Synthesis of quinazoline heterocyclic mutant PI3k-\u03b1 inhibitors treating cancers CLOVES and PROS syndrome patent WO2023192416. 2023."},{"key":"e_1_3_5_65_1","unstructured":"Combs AP Buesking AW Chen C et al. inventors; Prelude Therapeutics Incorporated assignee. Preparation of substituted quinazolinones as mutant PI3K-alpha inhibitors and their use as pharmaceuticals patent WO2024086789. 2024."},{"key":"e_1_3_5_66_1","unstructured":"Chen C Holmes R Maity S et al. inventors; Prelude Therapeutics Incorporated assignee. 3 4-dihydroquinazolinone compounds as PI3K\u03b1 inhibitors and their preparation pharmaceutical compositions and use in the treatment of diseases patent WO2024211346. 2024."},{"key":"e_1_3_5_67_1","unstructured":"Wang K Zhong W Wang Z et al. inventors; Qilu Regor Therapeutics Inc. assignee. 2-((1-(4-oxo-3 4-dihydroquinazolin-8-yl)ethyl)amino)benzoic acid derivatives as PI3K\u03b1 inhibitors and their preparation pharmaceutical compositions and use in the treatment of cancer patent WO2024000401. 2024."},{"key":"e_1_3_5_68_1","unstructured":"Arnautova Y Dardenne E Wrona I et al. inventors; Black Diamond Therapeutics Inc. assignee. Quinoxaline derivatives as PI3K alpha modulators and their preparation patent WO2024026419. 2024."},{"key":"e_1_3_5_69_1","unstructured":"Arnautova Y Dardenne E Wrona I et al. inventors; Black Diamond Therapeutics Inc. assignee. Preparation of quinoline derivatives as PI3K\u03b1 modulators and related uses patent WO2024026423. 2024."},{"key":"e_1_3_5_70_1","unstructured":"Dardenne E Wrona I Jewett I et al. inventors; Black Diamond Therapeutics Inc. assignee. Preparation of quinazolinone derivatives as PI3K\u03b1 modulators and related uses patent WO2024026424. 2024."},{"key":"e_1_3_5_71_1","unstructured":"Blake JF Boys ML Mareska DA et al. inventors; OnKure Inc. assignee. Preparation of ((4-oxo-3 4-dihydroquinazolin-8-yl)methyl)amine derivatives as PI3K inhibitors for the treatment of cancer patent WO2024064024. 2024."},{"key":"e_1_3_5_72_1","unstructured":"Blake JF Boys ML Mareska DA et al. inventors; Onkure Inc. assignee. Benzopyrimidin-4(3h)-ones as PI3K inhibitors patent WO2024081345. 2024."},{"key":"e_1_3_5_73_1","unstructured":"Busch B Stock NS Nagle A et al. inventors; Genesis Therapeutics Inc. assignee. Preparation of 4H-pyrido[1 2-a]pyrimidin-4-one derivatives for treating cancer patent WO2024081889. 2024."},{"key":"e_1_3_5_74_1","unstructured":"Chatterjee P Chicarelli MJ Conner ML et al. inventors; Cogent Biosciences Inc. assignee. Preparation of quinazoline derivatives as PI3k inhibitors patent WO2025029683. 2025."},{"key":"e_1_3_5_75_1","unstructured":"Qin L Guo Y Wang Z et al. Preparation of isoquinolinone and 4H-quinolizinone derivatives for the treatment of disease patent WO2024230803. 2024."},{"key":"e_1_3_5_76_1","unstructured":"Blake JF Boys ML Mareska DA et al. inventors; Onkure Inc. assignee. Preparation of isoquinolones as PI3K inhibitors patent WO2024054469. 2024."},{"key":"e_1_3_5_77_1","unstructured":"Blake JF Boys ML Mareska DA et al. inventors; OnKure Inc. assignee. Benzopyridinones and benzopyrimidinones as PI3K inhibitors and their preparation patent WO2025038395. 2025."},{"key":"e_1_3_5_78_1","unstructured":"Blake JF Boys ML Mareska DA et al. inventors; OnKure Inc. assignee. Preparation of quinolizinones as PI3K inhibitors patent WO2025207755. 2025."},{"key":"e_1_3_5_79_1","unstructured":"Blake JF Boys ML Mareska DA et al. inventors; OnKure Inc. assignee. Preparation of isoquinolones as PI3K inhibitors patent WO2025212360. 2025."},{"key":"e_1_3_5_80_1","unstructured":"Qin L Guo Y Wang Z et al. Quinoline derivatives and pharmaceutical compositions thereof for the treatment of disease patent WO2025021217. 2025."},{"key":"e_1_3_5_81_1","unstructured":"Busch B Reinus B Indarte M et al. inventors; Genesis Therapeutics Inc. assignee. Preparation of quinoline derivatives and uses thereof patent WO2025144931. 2025."},{"key":"e_1_3_5_82_1","unstructured":"Busch B Reinus B Vernier WF et al. inventors; Genesis Therapeutics Inc. assignee. Substituted 1-oxoisoindoline compounds for treating cancer patent WO2024229121. 2024."},{"key":"e_1_3_5_83_1","unstructured":"Buesking AW Holmes R inventors; Prelude Therapeutics Incorporated assignee. Preparation of heterocyclyl substituted phenyl(or pyridyl)ethylaminopicolinic acids as mutant PI3K-alpha inhibitors and their use as pharmaceuticals patent WO2025038815. 2025."},{"key":"e_1_3_5_84_1","unstructured":"Kuang R Tao R Wu Z et al. Phosphoinositide 3-kinase allosteric inhibitor for treating disease related to PI3k regulation patent WO2025040167. 2025."},{"key":"e_1_3_5_85_1","unstructured":"Cee VJ Tasker AS Walton M et al. inventors; Pivalent Therapeutics Inc. assignee. Preparation of 3 4-dihydroquinazolin-4-ones and related compounds as inhibitors of phosphoinositide 3-kinase (PI3K) and uses thereof patent WO2023159155. 2023."},{"key":"e_1_3_5_86_1","unstructured":"Zhou F Qi C Zheng H et al. inventors; Synnovation Therapeutics Inc. assignee. Preparation of tricyclic compounds as PI3K\u03b1 inhibitors patent WO2023230262. 2023."},{"key":"e_1_3_5_87_1","unstructured":"Dai X Yu Y Yang H et al. inventors; InventisBio Co. Ltd. InventisBio LLC assignee. Triazoloquinazoline compounds preparation methods and uses thereof patent WO2024051778. 2024."},{"key":"e_1_3_5_88_1","unstructured":"Dai X Yu Y Yang H et al. inventors; InventisBio Co. Ltd. InventisBio LLC assignee. Triazoloquinoxaline compounds preparation methods and uses thereof patent WO2025051235. 2025."},{"key":"e_1_3_5_89_1","unstructured":"Blake JF Boys ML Mareska DA et al. inventors; OnKure Inc. assignee. Preparation of compounds containing fused tricyclic rings as PI3K inhibitors patent WO2025255233. 2025."},{"key":"e_1_3_5_90_1","unstructured":"Clark CT Du Z Hung C-I et al. inventors; Gilead Sciences Inc. assignee. Preparation of benzofuro[3 2-c]pyridazine derivatives as PI3K\u03b1 inhibitors patent WO2025212599. 2025."},{"key":"e_1_3_5_91_1","unstructured":"Zhang C Zhao M Liu H et al. inventors; Xizang Haisco Pharmaceutical Co. Ltd. assignee. Carboxyl-containing heterocyclic derivative and pharmaceutical use thereof patent WO2024125644. 2024."},{"key":"e_1_3_5_92_1","unstructured":"Zhang C Zhao M Li L et al. inventors; Haisco Pharmaceutical Group Co. Ltd. assignee. Preparation of carboxyl group-containing tri-heterocyclic derivatives as antitumor agent patent CN120289439. 2025."},{"key":"e_1_3_5_93_1","unstructured":"Liu B inventor; Xuanzhu Biopharmaceutical Co. Ltd. assignee. Preparation of chromenone-based compounds as PI3K selective inhibitors patent CN118344325. 2024."},{"key":"e_1_3_5_94_1","unstructured":"Liu B Chen B inventors; Xuanzhu Biopharmaceutical Co. Ltd. assignee. Polycyclic compound capable of serving as PI3K\u03b1 inhibitor patent CN118359631. 2024."},{"key":"e_1_3_5_95_1","unstructured":"Fan X Chen Y Zheng L et al. inventors; Jiangsu Hengrui Pharmaceuticals Co. Ltd. Shanghai Hengrui Pharmaceutical Co. Ltd. assignee. Preparation of oxatetracyclic compounds as PI3Kalpha inhibitor in preventing and\/or treating PI3Kalpha-related diseases patent CN118791498. 2024."},{"key":"e_1_3_5_96_1","unstructured":"Zhao S Xu H Lu B et al. inventors; Changchun GeneScience Pharmaceutical Co. Ltd. assignee. Method for preparation of xanthenones as PI3K alpha inhibitors patent CN119219612. 2024."},{"key":"e_1_3_5_97_1","unstructured":"Qi C You L Zhou F et al. inventors; Synnovation Therapeutics Inc. assignee. Preparation of imidazoquinazolines pyrazoloisoquinolines and related compounds as PI3K\u03b1 inhibitors patent WO2023205680. 2023."},{"key":"e_1_3_5_98_1","unstructured":"Qi C Wu L Yao W et al. Heterocyclic compounds as PI3K\u03b1 inhibitors and their preparation patent WO2024151759. 2024."},{"key":"e_1_3_5_99_1","unstructured":"Zhang C Zhao M Yang D et al. inventors; Xizang Haisco Pharmaceutical Co. Ltd. assignee. Preparation of nitrogen-containing tricyclic derivatives as PI3K \u03b1 inhibitors patent CN118994111. 2024."},{"key":"e_1_3_5_100_1","unstructured":"Hua X Feng T Wang Z et al. inventors; Regor Pharmaceuticals Inc. assignee. Preparation of multicyclic PI3K inhibitors and use thereof patent WO2024260464. 2024."},{"key":"e_1_3_5_101_1","unstructured":"Niu C Zheng M Chen M et al. inventors; TYK Medicines (Zhengzhou) Inc. TYK Medicines Inc. assignee. Fused ring compound and use thereof patent WO2025026442. 2025."},{"key":"e_1_3_5_102_1","unstructured":"Niu C Zheng M Chen M et al. inventors; TYK Medicines (Zhengzhou) Inc. TYK Medicines Inc. assignee. Preparation of fused heterocyclic compounds as PI3K\u03b1 allosteric inhibitor for treating PI3K\u03b1-related diseases patent WO2025045106. 2025."},{"key":"e_1_3_5_103_1","unstructured":"Qi C Zhou F Li Y et al. inventors; Synnovation Therapeutics Inc. assignee. Preparation of 5-oxo-4 5-dihydroimidazo[1 5-a]quinazoline compounds as PI3K\u03b1 inhibitors patent WO2025085474. 2025."},{"key":"e_1_3_5_104_1","unstructured":"Harwood S Ketcham JM Aloiau ANG et al. inventors; Mirati Therapeutics Inc. assignee. Substituted spirocyclic-pyrroloquinazolinones and spirocyclic-piperidinoquinazolinones as PI3K inhibitors and their preparation patent WO2024148150. 2024."},{"key":"e_1_3_5_105_1","unstructured":"Bai Y Qi C Wu L et al. inventors; Synnovation Therapeutics Inc. assignee. Preparation of heterocyclic compounds as PI3K\u03b1 inhibitors patent WO2024163752. 2024."},{"key":"e_1_3_5_106_1","unstructured":"Boezio A Dipietro LV Fridrich CG et al. inventors; Relay Therapeutics Inc. D. E. Shaw Research LLC assignee. Preparation of isoindolinone derivatives as PI3K-\u03b1 inhibitors and methods of use thereof patent WO2021222556. 2021."},{"key":"e_1_3_5_107_1","unstructured":"Boezio A Taylor AM Fridrich CG et al. inventors; Relay Therapeutics Inc. assignee. Preparation of heterocycles as PI3K\u03b1 inhibitors and methods of use thereof patent WO2023288242. 2023."},{"key":"e_1_3_5_108_1","unstructured":"Xiao H Su Y Zhou X et al. inventors; Shanghai Hansoh Biomedical Co. Ltd. Jiangsu Hansoh Pharmaceutical Group Co. Ltd. assignee. Dibicyclic derivative regulator preparation method and application thereof patent CN117229281. 2023."},{"key":"e_1_3_5_109_1","unstructured":"Hu Z Tang F Zhou F et al. inventors; Nanjing Zaiming Pharmaceutical Co. Ltd. assignee. Preparation of tricyclic compound and use for treating a PI3K\u03b1-related disease patent WO2024055992. 2024."},{"key":"e_1_3_5_110_1","unstructured":"Xiao H Fan B Liu Y et al. inventors; Shanghai Hansoh Biomedical Co. Ltd. Jiangsu Hansoh Pharmaceutical Group Co. Ltd. assignee. Fused heterocyclic derivatives inhibitors methods of making and uses thereof patent CN118530251. 2024."},{"key":"e_1_3_5_111_1","unstructured":"Zheng Z Li P Li S et al. inventors; Academy of Military Medical Sciences (AMMS) assignee. Novel 1 2-dihydropyrrolo[1 2-a]pyrazin-3-one derivatives for selective PI3K\u03b1 mutant inhibition and anticancer therapy patent CN121045188. 2025."},{"key":"e_1_3_5_112_1","unstructured":"Boezio A Taylor AM Gunaydin H et al. inventors; Relay Therapeutics Inc. D. E. Shaw Research LLC assignee. Preparation of heterocycles as PI3K-alpha inhibitors and methods of use thereof patent WO2023039532. 2023."},{"key":"e_1_3_5_113_1","unstructured":"Qi C Pan J Wu L et al. inventors; Synnovation Therapeutics Inc. assignee. Preparation of heterocyclic compounds as PI3K\u03b1 inhibitors patent WO2023239846. 2023."},{"key":"e_1_3_5_114_1","unstructured":"Xiao H Zhou X Wu G et al. inventors; Jiangsu Hansoh Pharmaceutical Group Co. Ltd. Shanghai Hansoh Biomedical Co. Ltd. assignee. Preparation of pyridopyridine derivatives as PI3K\u03b1 inhibitors and application thereof patent CN118724895. 2024."},{"key":"e_1_3_5_115_1","unstructured":"Xiao H Su Y Deng H et al. inventors; Shanghai Hansoh Biomedical Co. Ltd. Jiangsu Hansoh Pharmaceutical Group Co. Ltd. assignee. Fused ring derivative preparation method therefor and application thereof patent WO2023098880. 2023."},{"key":"e_1_3_5_116_1","unstructured":"Qi C Pan J Yang J et al. inventors; Synnovation Therapeutics Inc. assignee. PI3K\u03b1 inhibitors and their use in treatment of conditions associated with PI3Ka patent WO2023168378. 2023."},{"key":"e_1_3_5_117_1","unstructured":"Li M Liu T Feng J et al. inventors; ENSEM Therapeutics Inc. assignee. Tricyclic aryl derivatives as PI3K\u03b1 inhibitors and their preparation patent WO2024026128. 2024."},{"key":"e_1_3_5_118_1","unstructured":"Li M Liu T inventors; ENSEM Therapeutics Inc. assignee. Tricyclic aryl derivatives as PI3K\u03b1 inhibitors and their preparation patent WO2024026129. 2024."},{"key":"e_1_3_5_119_1","unstructured":"Xu Z Xia L Li X et al. inventors; Shanghai Yingli Pharmaceutical Co. Ltd. assignee. Preparation of nitrogen-containing heterocyclic compound its pharmaceutical composition and application patent WO2024051784. 2024."},{"key":"e_1_3_5_120_1","unstructured":"Xiao H Su Y Yu W et al. inventors; Shanghai Hansoh Biomedical Co. Ltd. Jiangsu Hansoh Pharmaceutical Group Co. Ltd. assignee. Polycyclic ring-fused derivative preparation method and application as PI3Kalpha inhibitor patent WO2024094163. 2024."},{"key":"e_1_3_5_121_1","unstructured":"Wang J Hu Z Sun T et al. inventors; Nanjing Zaiming Pharmaceutical Co. Ltd. assignee. Tetracyclic compound and use thereof patent WO2024153238. 2024."},{"key":"e_1_3_5_122_1","unstructured":"Xun G Yang J Zhou J et al. inventors; Shenzhen Zhongge Biological Technology Co. Ltd. assignee. Preparation of tricyclic heterocyclic compounds as PI3K\u03b1 inhibitor for treating PI3K\u03b1-mediated diseases or conditions patent CN118930543. 2024."},{"key":"e_1_3_5_123_1","unstructured":"Xiao H Fan B Wu G et al. inventors; Shanghai Hansoh Biomedical Co. Ltd. Jiangsu Hansoh Pharmaceutical Group Co. Ltd. assignee. Cyclic derivative regulator preparation method and application thereof patent CN119954810. 2025."},{"key":"e_1_3_5_124_1","unstructured":"Li M Liu T inventors; ENSEM Therapeutics Inc. assignee. Preparation of urea derivatives of tricyclic compounds and compositions and methods thereof patent WO2025165834. 2025."},{"key":"e_1_3_5_125_1","unstructured":"Li M Liu T Deng H et al. Anilino tricyclic compounds and compositions and methods thereof patent WO2025165835. 2025."},{"key":"e_1_3_5_126_1","unstructured":"Li M Liu T inventors; ENSEM Therapeutics Inc. assignee. Preparation of guanidino tricyclic compounds and compositions and methods thereof patent WO2025165839. 2025."},{"key":"e_1_3_5_127_1","unstructured":"Xu Z Xia L Yang H et al. Compound with tricyclic structure pharmaceutical composition thereof and use thereof patent WO2025179441. 2025."},{"key":"e_1_3_5_128_1","unstructured":"St Jean D Jr. Cummings MD inventors; Scorpion Therapeutics Inc. assignee. Substituted urea derivatives as PI3K inhibitors and their preparation and use in the treatment of cancer patent WO2022265993. 2022."},{"key":"e_1_3_5_129_1","unstructured":"St Jean D Jr. Brooijmans N Guzman-Perez A et al. Methods for treating cancer patent WO2024077036. 2024."},{"key":"e_1_3_5_130_1","unstructured":"Zhao S Xu H Lu B et al. inventors; Changchun GeneScience Pharmaceutical Co. Ltd. assignee. Pi3k\u03b1 inhibitor compound pharmaceutical composition and use thereof patent WO2024199430. 2024."},{"key":"e_1_3_5_131_1","unstructured":"Li M Zhang R Chen C-Y et al. inventors; Laekna Pharmaceutical Ningbo Co. Ltd. assignee. Preparation of benzofuran compounds and their use as PI3K alpha inhibitors patent WO2024222894. 2024."},{"key":"e_1_3_5_132_1","unstructured":"Kuang R Hu Z inventors; Shanghai Allist Pharmaceuticals Co. Ltd. assignee. Preparation of benzofuranyl pyrimidine derivatives as PI3K inhibitor and their application patent CN120329285. 2025."},{"key":"e_1_3_5_133_1","unstructured":"Zhao S Xu H Jia X et al. inventors; Changchun GeneScience Pharmaceutical Co. Ltd. assignee. Preparation of benzofuranyl urea derivatives as PI3K\u03b1 inhibitor pharmaceutical compositions and their application patent WO2025190225. 2025."},{"key":"e_1_3_5_134_1","unstructured":"Zhao S Xu H Jia X et al. inventors; Changchun GeneScience Pharmaceutical Co. Ltd. assignee. Preparation method of thiophene compounds as PI3K alpha inhibitor and their application patent CN120865177. 2025."},{"key":"e_1_3_5_135_1","unstructured":"Li M Zhang R Chen C-Y et al. inventors; Laekna Pharmaceutical Ningbo Co. Ltd. assignee. Heteroaryl compounds and their use as PI3K alpha inhibitors patent WO2025247348. 2025."},{"key":"e_1_3_5_136_1","unstructured":"St Jean D inventor; Scorpion Therapeutics Inc. assignee. Preparation of benzimidazoles and related heterocycles as PI3K isoform alpha inhibitors useful in treatment of cancer patent WO2023018636. 2023."},{"key":"e_1_3_5_137_1","unstructured":"Zhao S Xu H Lu B et al. inventors; Changchun GeneScience Pharmaceutical Co. Ltd. assignee. Preparation of pyrimidine containing Pi3k\u03b1 inhibitor compounds and its applications patent CN120118074. 2025."},{"key":"e_1_3_5_138_1","unstructured":"Dai X Niu H Yang H et al. inventors; InventisBio Co. Ltd. InventisBio LLC assignee. Quinazolin-4-one compounds preparation methods and uses thereof patent WO2024183806. 2024."},{"key":"e_1_3_5_139_1","unstructured":"Dai X Niu H Yang H et al. inventors; InventisBio Co. Ltd. InventisBio LLC assignee. Compounds preparation methods and uses thereof patent WO2025201503. 2025."},{"key":"e_1_3_5_140_1","unstructured":"Dai X Niu H Yang H et al. inventors; InventisBio Co. Ltd. InventisBio LLC assignee. Benzofuran derivatives as PI3K inhibitors and their preparation patent WO2025016314. 2025."},{"key":"e_1_3_5_141_1","unstructured":"Li M Zhang R Chen C-Y et al. inventors; Laekna Pharmaceutical Ningbo Co. Ltd. assignee. Multicyclic compounds as PI3K alpha inhibitors and their preparation patent WO2025036439. 2025."},{"key":"e_1_3_5_142_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA1008"},{"key":"e_1_3_5_143_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00648-0"},{"key":"e_1_3_5_144_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2017.09.009"},{"key":"e_1_3_5_146_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00679"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c03368"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0704"},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051416"},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612822666160614000053"},{"key":"e_1_3_5_151_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501796"},{"key":"e_1_3_5_152_1","doi-asserted-by":"publisher","DOI":"10.1200\/OA-25-00041"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2704853","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543776.2026.2704853","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2704853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:26:20Z","timestamp":1788258380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2704853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":150,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,2]]}},"alternative-id":["10.1080\/13543776.2026.2704853"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2704853","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}